Log In
Print this Print this

Peptide vaccine (CV-MG01)

  Manage Alerts
Collapse Summary General Information
Company CuraVac Inc.
DescriptionPeptide mimicking antigen receptors on autoimmune B cells and T cells associated with myasthenia gravis
Molecular Target
Mechanism of ActionVaccine; Immunotherapy
Therapeutic ModalityPreventive vaccine: Peptide vaccine
Latest Stage of DevelopmentPhase I
Standard IndicationMyasthenia gravis
Indication DetailsTreat myasthenia gravis
Regulatory Designation U.S. - Orphan Drug (Treat myasthenia gravis);
EU - Orphan Drug (Treat myasthenia gravis)

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today